Article
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Blood - 28 Aug 2025
Arellano Martha L, Thirman Michael J, DiPersio John F, Heiblig Maël, Stein Eytan M, Schuh Andre C, Žučenka Andrius, de Botton Stephane, Grove Carolyn S, Mannis Gabriel N, Papayannidis Cristina, Perl Alexander E, Issa Ghayas C, Aldoss Ibrahim, Bajel Ashish, Dickens David S, Kühn Michael W M, Mantzaris Ioannis, Raffoux Emmanuel, Traer Elie, Amitai Irina, Döhner Hartmut, Greco Corinna, Kovacsovics Tibor, McMahon Christine M, Montesinos Pau, Pigneux Arnaud, Shami Paul J, Stone Richard M, Wolach Ofir, Harpel John G, Chudnovsky Yakov, Yu Li, Bagley Rebecca G, Smith Angela R, Blachly James S
Abstract excerpt
ABSTRACT: The prognosis for relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a potent, selective menin inhibitor, was recently approved for the treatment of R/R acute leukemia with a KMT2A translocation in patients aged ≥1 year based on results from the phase 1/2 AUGMENT-101 study. Here, we present results...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.